Literature DB >> 4808709

The role of properdin in the alternate pathway of complement activation.

O Götze, H J Müller-Eberhard.   

Abstract

Properdin (P), a highly basic euglobulin, was purified from human serum to molecular homogeneity without the use of zymosan. Isolated P was found to efficiently initiate activation of the alternate pathway of complement activation (C3 activator or properdin system) and to be an essential component during its early reaction stages. The activity of isolated P did not require the presence of an activating polysaccharide. It was therefore concluded that purified P had been obtained in an activated form (P). In an isolated reaction system containing purified C3, C3 proactivator (C3PA), and C3 proactivator convertase (C3PAse), P was able to mediate the activation of C3PAse which in turn activated C3PA to cleave C3. This activation of C3PAse was found to depend on the presence of native C3. These results allowed the formulation of a concept in which P is envisaged to act as a modulator of native C3 enabling it to activate C3PAse. Activation of C3 was efficiently mediated by P in the fluid phase. Efficient activation of C5, however, required the participation of an insoluble polysaccharide (zymosan). The possibility is raised therefore that P might also be an integral part of the multimolecular C5 convertase of the alternate pathway of complement activation.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4808709      PMCID: PMC2139515          DOI: 10.1084/jem.139.1.44

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  The properdin system and immunity. XII. Assay, properties and partial purification of a hydrazine-sensitive serum factor (factor A) in the properdin system.

Authors:  J PENSKY; L WURZ; L PILLEMER; I H LEPOW
Journal:  Z Immun exp ther       Date:  1959 Oct-Nov

2.  Biologically active water-insoluble protein polymers. I. Their use for isolation of antigens and antibodies.

Authors:  S Avrameas; T Ternynck
Journal:  J Biol Chem       Date:  1967-04-10       Impact factor: 5.157

3.  A new buffer system for disc electrophoresis suitable for slightly basic proteins.

Authors:  H Tamura; N Ui
Journal:  J Biochem       Date:  1972-03       Impact factor: 3.387

4.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

5.  Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.

Authors:  H J Müller-Eberhard; K E Fjellström
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

6.  The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis.

Authors:  N R Cooper; M J Polley; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1970-04

7.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.

Authors:  O Götze; H J Müller-Eberhard
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

8.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

9.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  39 in total

1.  The effect of anticomplementary substances on properdin in normal and C2-deficient sera.

Authors:  R H McLean; K Townsend; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

2.  Changes in humoral components of host defense following burn trauma.

Authors:  A B Bjornson; W A Altemeier; H S Bjornson
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

3.  Mechanism of complement activation by radiographic contrast media.

Authors:  C M Arroyave; E M Tan
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

4.  [Relations between complement and blood coagulation (author's transl)].

Authors:  G Müller-Berghaus
Journal:  Klin Wochenschr       Date:  1977-07-15

5.  PEGylation of model drug carriers enhances phagocytosis by primary human neutrophils.

Authors:  William J Kelley; Catherine A Fromen; Genesis Lopez-Cazares; Omolola Eniola-Adefeso
Journal:  Acta Biomater       Date:  2018-09-06       Impact factor: 8.947

6.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

7.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

8.  Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.

Authors:  C Adam; D G Williams; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

9.  Contribution of immunoglobulins M and G, complement, and properdin to the intracellular killing of Escherichia coli by polymorphonuclear leukocytes.

Authors:  J Menzel; H Jungfer; D Gemsa
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  Increased antibacterial activity against Escherichia coli in bovine serum after the induction of endotoxin tolerance.

Authors:  A W Hill; A L Shears; K G Hibbitt
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.